KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

CRISPR Therapeutics AG (CRSP) Accounts Payables: 2015-2025

Historic Accounts Payables for CRISPR Therapeutics AG (CRSP) over the last 9 years, with Sep 2025 value amounting to $11.8 million.

  • CRISPR Therapeutics AG's Accounts Payables fell 24.26% to $11.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $11.8 million, marking a year-over-year decrease of 24.26%. This contributed to the annual value of $14.7 million for FY2024, which is 61.44% down from last year.
  • CRISPR Therapeutics AG's Accounts Payables amounted to $11.8 million in Q3 2025, which was up 20.97% from $9.8 million recorded in Q2 2025.
  • In the past 5 years, CRISPR Therapeutics AG's Accounts Payables registered a high of $45.2 million during Q1 2023, and its lowest value of $9.5 million during Q2 2024.
  • Over the past 3 years, CRISPR Therapeutics AG's median Accounts Payables value was $15.6 million (recorded in 2024), while the average stood at $20.7 million.
  • Its Accounts Payables has fluctuated over the past 5 years, first soared by 215.87% in 2022, then tumbled by 65.74% in 2024.
  • CRISPR Therapeutics AG's Accounts Payables (Quarterly) stood at $14.8 million in 2021, then spiked by 85.12% to $27.4 million in 2022, then skyrocketed by 39.08% to $38.1 million in 2023, then slumped by 61.44% to $14.7 million in 2024, then dropped by 24.26% to $11.8 million in 2025.
  • Its Accounts Payables was $11.8 million in Q3 2025, compared to $9.8 million in Q2 2025 and $13.1 million in Q1 2025.